reports
PCI Biotech half-year interim 2025 report
PCI Biotech half-year interim 2025 report Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achieving successful results at this scale was a critical ris...
PCI Biotech: Invitation to first half 2025 results presentation and co...
PCI Biotech: Invitation to first half 2025 results presentation and corporate update Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time). The presentation will be held in Norwegian as a live webcast available through There will be a Q&A session at the end of the presentation. Please submit questions to prior to the webcast. It will be possible to post written questions through the webcast console during the session. The interim report and ...
PCI Biotech announces discontinuation of development of the PCL techno...
PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing. Today’s decision is primarily based on the insufficient progress towards the 2025 goal of demonstrating improved yield in mini benchtop bioreactors. Achieving successful end-to-end results in small bioreactors is a critical risk-reducing milestone for further development. Fol...
PCI Biotech: Minutes of Annual General Meeting 2025
PCI Biotech: Minutes of Annual General Meeting 2025 Oslo, 22 May 2025. The Annual General Meeting in PCI Biotech Holding ASA took place today, 22 May 2025. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, , Mobile: This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. Attachment ...
PCI BIotech: Disclosure of voting rights for Chair of the Board
PCI BIotech: Disclosure of voting rights for Chair of the Board Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 22 May 2025. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 3,957,330 additional shares. In total, Mr. Bøhn will represent and vote for...
Notice of Annual General Meeting 2025
Notice of Annual General Meeting 2025 Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website . For further information, please contact: Ronny Skuggedal, CEO/CFO, E-mail: Office: Mobile: This information is subject to the disclosure requirements pursuant to section 5-12 of t...
PCI Biotech Holding ASA: Annual Report 2024
PCI Biotech Holding ASA: Annual Report 2024 Oslo, Norway, April 24, 2025The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2024. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2024 is also available on the company’s website For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, , Mobile: 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwe...
PCI Biotech full year 2024 interim results
PCI Biotech full year 2024 interim results Oslo (Norway), 27 February 2025 – PCI Biotech (OSE: PCIB), today announces its preliminary full year 2024 results. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech’s 2024 development goals were to demonstrate scalability and manufacturing process benefits of the photochemical-based technology (PCL) in viral vector (AAV) manufacturing by advancing the technology into mini benchtop bioreactors, which are considered representative for commercial manufacturing. Recent mini benchtop bioreactor results...
PCI Biotech: Invitation to preliminary full-year 2024 results presenta...
PCI Biotech: Invitation to preliminary full-year 2024 results presentation Oslo, Norway, 25 February 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's full-year 2024 interim report on Thursday 27 February 2025, 08:30am – 09:00am CET (local time). The presentation will be held as a live webcast available through The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made available on and...
PCI Biotech: Employee share option scheme in connection with promotion...
PCI Biotech: Employee share option scheme in connection with promotion of new CSO Oslo, 10 January 2025 - PCI Biotech (OSE: PCIB), today announced that the Board of Directors has granted share options to Morten Luhr who has been promoted to Chief Scientific Officer (CSO) from January 2025. Anders Høgset, former CSO, will commence as Scientific Advisor in a 20% position. In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI B...
PCI Biotech: Employee share option scheme
PCI Biotech: Employee share option scheme Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 885,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech’s choice), a...
PCI Biotech first half 2024 interim results
PCI Biotech first half 2024 interim results Oslo (Norway), 28 August 2024 – PCI Biotech (OSE: PCIB), today announces its interim first half 2024 results. Please find enclosed the interim report and presentation.Highlights review OperationsPCI Biotech’s 2024 development goals are to demonstrate scalability and manufacturing process benefits for the photochemical-based technology (PCL) in viral vector manufacturing. Results reported in Q1 2024 from field testing of the technology with a European partner confirmed the potential benefit of applying photochemical methods in...
PCI Biotech: Invitation to first half interim 2024 results presentatio...
PCI Biotech: Invitation to first half interim 2024 results presentation Oslo, Norway, 23 August 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2024 interim report on Wednesday 28 August 2024, 08:30am – 09:00am CEST (local time). The presentation will be held as a live webcast available through The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made available on and o...
Minutes of Annual General Meeting 2024
Minutes of Annual General Meeting 2024 Oslo, 24 May 2024. The Annual General Meeting in PCI Biotech Holding ASA took place today, 24 May 2024. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, , Mobile: This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. Attachment ...
Disclosure of voting rights for Chair of the Board
Disclosure of voting rights for Chair of the Board Oslo, 23 May 2024. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 24 May 2024. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 4,288,185 additional shares. In total, Mr. Bøhn will represent and vote for 11.8 percent...
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024 Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website . For further information, please contact:Ronny Skuggedal, CEO/CFO, E-mail: Office: Mobile: This information is subject to the disclosure requirements...
PCI Biotech Holding ASA - Annual Report 2023
PCI Biotech Holding ASA - Annual Report 2023 Oslo, Norway, April 26, 2024.The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, , Mobile: 757This information is subject to the disclosure requirements pursuant to section 5...
PCI Biotech second half 2023 interim results
PCI Biotech second half 2023 interim results Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review OperationsThe use of fimaNAc in gene therapy manufacturing has since its inception in 2022 generated results supporting the notion of applying photochemical methods to increase yield and reduce impurities in bioprocessing, specifically viral vector manufacturing. The most recently reported 2023 milestone was initiation of field testing in Q4 with an internat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.